Stylus Medicine

In vivo genome editing for CAR-T

Scientist - Genome Sciences & Engineering

Translational Research & Bench BiologyConfirmed live in the last 24 hours

Full-timeCambridge, MA, USA$125k - $140kIn-person

About the Job

Requirements

A PhD in Cell Biology, Molecular Biology, or a related field; alternatively, an MS with at least 5 years or a BS with at least 7 years of relevant experience.
Hands-on experience with LNP delivery and expertise culturing primary cells, including T-cells and hepatocytes, and/or cancer cell lines.
Working knowledge of gene-editing technologies such as CRISPR nucleases, recombinases, base editors, or transcriptional effectors.
Experience with flow cytometry and laboratory automation platforms for cell-based screening workflows.
Proficiency in nucleic acid quality-control methods, including TapeStation, Qubit, NanoDrop, and quantitative polymerase chain reaction.
A track record of independently generating reproducible data and performing rigorous quantitative analysis.
Strong written and verbal communication skills, including presenting complex technical information to specialist and non-specialist audiences.
Organizational skills and comfort managing complex datasets and overlapping projects.
Ability to plan and prioritize for scientific impact.
Ability to communicate complex concepts clearly across disciplines.
A collaborative, team-oriented approach.
Problem-solving ability in conditions of scientific uncertainty.

Responsibilities

Design and execute in vitro functional assays to support candidate selection and preclinical development of lead genome editors and advance platform and program objectives.
Develop and optimize molecular assays, including droplet digital polymerase chain reaction and quantitative polymerase chain reaction, and cytogenetic assays, including KromaTiD and optical genome mapping, to measure genome-editor activity, specificity, transgene copy number, T-cell receptor repertoire, and biodistribution.
Support genome-editor engineering campaigns by running high-throughput screens in relevant cell lines, including primary human T-cells, and deliver timely, decision-quality data to guide candidate selection.
Troubleshoot experiments, analyze data, and translate results into actionable scientific insights.
Maintain detailed laboratory notebooks and communicate data and findings to the broader scientific team.
Partner across R&D to advance optimized candidates into translational and preclinical development.

About Stylus Medicine:

Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The company’s approach is versatile and modular, with potential therapeutic application across oncology, autoimmune, genetic diseases, and beyond.

About the Role:

Stylus Medicine is seeking a Scientist to join our Genome Sciences & Engineering team to drive innovation in next-generation gene editing therapies. In this role, the Scientist will drive the in vitro functional assessment of the company’s lead genome editors to support the advancement of the company’s lead programs through translational and preclinical development. This individual will play a key role in discovery and engineering efforts, advancing LSR-based genome editing platforms and collaborating across diverse R&D teams.

Key Responsibilities & Accountabilities:

Design and execute in vitro functional assays that support candidate selection and preclinical development of lead genome editors,advancing platform and program objectives
Develop and optimize molecular (ddPCR, qPCR) and cytogenetic (KromaTiD, optical genome mapping) assays to measure genome editor activity, specificity, transgene copy number, TCR repertoire, and biodistribution
Support genome editor engineering campaigns by running high-throughput screens in relevant cell lines, including primary human T-cells, and delivering timely, decision-quality data to guide candidate selection
Troubleshoot experiments, analyze data, and translate results into actionable scientific insights
Maintain detailed laboratory notebooks and clearly communicate data and findings to the broader scientific team
Partner across R&D to advance optimized candidates into translational and preclinical development

Qualifications & Skills:

PhD in Cell Biology, Molecular Biology, or a related field; or MS with 5+ years or BS with 7+ years of relevant experience
Hands-on experience with LNP delivery and expertise culturing primary cells (including, but not limited to T-cells and hepatocytes) and/or cancer cell lines
Working knowledge of gene editing technologies (CRISPR nucleases, recombinases, base editors, or transcriptional effectors)
Experience with flow cytometry and laboratory automation platforms for cell-based screening workflows
Proficiency in nucleic acid QC methods, including TapeStation, Qubit, NanoDrop, and qPCR
Track record of independently generating reproducible data and performing rigorous quantitative analysis
Strong written and verbal communication skills, with the ability to present complex technical information to both specialist and non-specialist audiences
Exceptional organizational skills, comfortable managing complex datasets and overlapping projects
Strategic thinker who plans and prioritizes for scientific impact
Clear, approachable communicator who makes complex concepts accessible across disciplines
Collaborative mindset with a team-first attitude
Decisive problem-solver who thrives amid scientific uncertainty

Pay Range: $125,000 - $140,000

About the Company

Stylus Medicine

In vivo genome editing for CAR-T

Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.

Company size: 11-50
Company stage: Series A
Total funding: $85M
Headquarters: Cambridge, MA
Founded: 2022

Recently Posted Jobs

Explore more opportunities at Stylus Medicine

See more jobs